Bespoke assays to screen compounds against exciting new DUB targets as they continue to emerge across a wide range of human diseases
Our extensive expertise in the Ubiquitin Proteosome System (UPS) combined with access to our high-quality reagents allows Ubiquigent™’s Custom Assay Development team to support biotech and pharma in translating new discoveries in this rapidly emerging space into drug discovery programmes.
Ubiquigent has successfully developed and delivered many high-throughput assays for screening projects against UPS targets of high therapeutic value, such as DUBs and E3 ligases.